Analysts/Institutional Investor Meet/Con. Call Updates

July 14, 2026 DCS-CRD Listing Compliance BSE Limited National Stock Exchange of India Limited First Floor, New Trade Wing Exchange Plaza, 5th Floor Rotunda Building, Phiroze Jeejeebhoy Towers Plot No. C/1, ‘G’ Block, Bandra- Kurla Complex Dalal Street, Fort Mumbai 400001 Bandra East Mumbai 400051 Fax No.2272 3121/2037/2039 Fax No.2659 8237/8238 Stock Code: 543213 Stock Code: ROSSARI Dear Sir/Madam, Sub: Intimation of Earnings Conference Call for investors and analysts for Q1 FY27 Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby intimate that an Earnings Conference Call for investors and analysts is being organized by the Company, as per the details provided below: Day and Time Name of Conference/ Meeting Type Scheduled for Date Investor/ Analysts Monday, 05:00 PM Q1 FY27 Conference Call - Investors/ July 20, (IST) Earnings Conference Call Group Meet Analyst Group 2026 (Telecommunication) The said conference call will be initiated with a brief management discussion on the financial results for the Quarter ended June 30, 2026, followed by an interactive Question & Answer session. Invite in this regard is enclosed for your information and record. The same may please be taken on record and suitably disseminated to all concerned. Thanking you, Yours Sincerely, For Rossari Biotech Limited Parul Gupta Company Secretary & Head - Legal Membership No.: A38895 Encl.: as above Rossari Biotech Limited Q1 FY27 Earnings Conference Call Monday, July 20, 2026, at 5:00 p.m. IST Rossari Biotech Limited (Rossari) will host a conference call for investors and analysts on Monday, July 20, 2026, at 5:00 pm IST. The conference call will be initiated with a brief management discussion on the Q1 FY27 results, to be declared on Saturday, July 18, 2026, followed by an interactive Question & Answer session. Senior Management team of the Company will be present to address the call. Dial-in details are as follows: Timing 5:00 p.m. IST on Monday, July 20, 2026 Universal dial-in + 91 22 6280 1141 / 7115 8042 To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link: Pre-registration (Zero wait time to join the call) Page | 1 About Rossari: Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India. For more information, please visit www.rossari.com OR contact: Ketan Sablok Anoop Poojari / Mitesh Jain Rossari Biotech Limited CDR India Tel: +91 22 6123 3800 Tel: +91 98330 90434 / 96194 44691 Email: ketan.sablok@rossari.com Email: anoop@cdr-india.com mitesh@cdr-india.com DISCLAIMER: Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, import duties, litigation, labour relations etc. Actual results might differ substantially from those expressed or implied. Rossari Biotech Ltd will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. Page | 2